Skip to main content

Legal Update

Biotech Start-up Funding: An Ounce of Prevention Is Worth a Pound of Cure

10 October 2017
Mayer Brown Legal Update

Subject to certain limitations, investors can choose between providing debt and equity funding to a start-up company. In cases in which the venture turns out to be unsuccessful, debt financing can provide significant tax advantages to the investor in the form of ordinary bad debt deductions. The recent US Tax Court case of Rutter v. Commissioner demonstrates the importance of proper tax planning in order to sustain the characterization of an advance to a biotech start-up as indebtedness for federal income tax purposes. Mark Leeds of the New York office of Mayer Brown analyzes this new case and provides insights on tax planning for investing in start-ups in the attached Mayer Brown Legal Update.

This Legal Update was republished in the February 2018 edition of Intellectual Property & Technology Law Journal.

The Build a Report feature requires the use of cookies to function properly. Cookies are small text files that are placed on your computer by websites that you visit. They are widely used in order to make websites work, or work more efficiently. If you do not accept cookies, this function will not work. For more information please see our Privacy Policy

You have no pages selected. Please select pages to email then resubmit.